http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101918456-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-102 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2827 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39533 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 |
| filingDate | 2015-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101918456-B1 |
| titleOfInvention | Antibodies Capable of Binding Specifically to CD80 and CD86 |
| abstract | The present invention relates to novel antibodies to CD80 and CD86 used in the prevention or treatment of rheumatoid arthritis. The antibody of the present invention is an antibody that specifically binds CD80 and / or CD86 that is overexpressed in a cell. The antibodies of the present invention have homology to the sequences because they have very low homology compared to the CDR sequences of conventional CD80 and / or CD86 target antibodies. The antibody of the present invention has the ability to inhibit T cell activity equivalent to that of avatacept used in the treatment of rheumatoid arthritis in a single treatment and has remarkably superior ability to inhibit T cell activity than the avatacept when the CD80 target antibody and the CD86 target antibody are used in combination And is very effective in the prevention or treatment of rheumatoid arthritis. |
| priorityDate | 2015-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 627.